Application of artificial intelligence in biomarker identification and immunothera-py of lung cancer
10.13315/j.cnki.cjcep.2025.06.014
- VernacularTitle:人工智能在肺癌的生物学标志物识别及免疫治疗中的应用
- Author:
Lei FAN
1
;
Liya DING
;
Zhinong JIANG
Author Information
1. 浙江大学附属邵逸夫医院病理科,杭州 310016;浙江省宁海县中医医院病理科,宁波 315600
- Publication Type:Journal Article
- Keywords:
lung cancer;
artificial intelligence;
biomarkers;
immunotherapy
- From:
Chinese Journal of Clinical and Experimental Pathology
2025;41(6):782-788
- CountryChina
- Language:Chinese
-
Abstract:
In 2022,there were approximately 1.06 million new cases and 733 000 deaths from lung cancer,with a 5-year survival rate of approximately 20％for advanced lung cancer.In recent years,the identification of immune checkpoint molecules such as PD-1,PD-L1,and CTLA-4 has led to significant advancements in immunotherapy strate-gies for advanced lung cancer,particularly in the development and application of predictive biomarkers.These new ap-proaches have improved the efficacy of traditional modalities such as surgery,chemotherapy,and radiotherapy.Howev-er,the evaluation and selection of patients likely to benefit from targeted biomarkers remain partially subjective.This review summarized how artificial intelligence(AI)can assist in improving the accuracy of biomarker identification and the effectiveness of immunotherapy for lung cancer.This review discussed the current treatment status of lung cancer,the application of AI in biomarker identification,and the prediction and evaluation of immunotherapy outcomes,aiming to provide valuable guidance and reference for clinicians.
